Clinical Trial Update: Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating the combination of difluoromethylornithine (DFMO) with bortezomib in relapsed or refractory neuroblastoma has completed, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Bortezomib (bortezomib)
• Difluoromethylornithine (DFMO) (difluoromethylornithine)

Snippet

Sponsor: Giselle Sholler | Conditions: Neuroblastoma Recurrent | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-04-25